Artiva Biotherapeutics — Q3 2026 Earnings Summary

Financial Performance:

• As of September 30, 2026, the Company reported approximately $319.1 million in cash, cash equivalents, and investments (preliminary and unaudited).
• No revenue, earnings, profit margins, or debt figures are disclosed in the press release.
• The Company is implementing a workforce reduction of approximately 94% to preserve capital.

Guidance and Future Outlook:

• The Company has discontinued further development of AlloNK® (AB-101), including the planned Phase 3 pivotal trial.
• The Board of Directors is evaluating strategic alternatives to maximize stockholder value, which may include a merger, business combination, sale or licensing of assets, dissolution, or liquidation.
• No further updates on strategic alternatives will be provided until the Board approves a specific course of action, the process concludes, or disclosure is required by law.
• Updated clinical data may be presented at future scientific meetings depending on the outcome of the strategic review.

Business Segments and Product Lines:

• Development of AlloNK® (AB-101), a non-genetically modified allogeneic NK cell therapy for rheumatoid arthritis and other B-cell-driven autoimmune diseases, has been halted.
• Updated clinical data showed deep B cell depletion and clinical activity consistent with previous findings, but longer-term follow-up indicated the durability of clinical response did not meet the Company's required threshold.
• The Company will not initiate the planned Phase 3 trial and will not dose any additional patients in ongoing AlloNK studies.
• The Company canceled its previously announced clinical data presentation at ACR Convergence 2026 and its investor webcast scheduled for November 9, 2026.

Market and Competitive Landscape:

• No specific market share, competitor names, or market trend data are provided in the press release.

Risks and Challenges:

• Two Grade 5 safety events occurred: one fatal neurological event (leukoencephalopathy) assessed as likely related to fludarabine-associated neurotoxicity, and a second sudden death assessed as unrelated to the study treatment.
• The FDA requested a pause on enrollment and dosing in the Phase 2a study following the first safety event.
• The discontinuation of the lead candidate represents a significant risk to the Company's operational continuity and future value.

Management Commentary and Tone:

• CEO Fred Aslan, M.D., described the decision to discontinue AlloNK and pursue strategic alternatives as "difficult."
• Management emphasized that patient safety and well-being were the highest priorities and expressed deep sadness regarding the deaths of two patients.
• The Company intends to share details of the fludarabine toxicity case in a scientific publication.

Other Key Points:

• Leerink Partners has been engaged as the financial advisor to assist in the evaluation of strategic alternatives.
• The preliminary cash balance as of September 30, 2026, is unaudited and subject to adjustment; complete results will be included in the Form 10-Q for the quarter ended September 30, 2026.
• The Company will work with the FDA, investigators, and institutional review boards to ensure an orderly close-out of clinical development, including continued safety monitoring.